MIAMI – The lack of progress in development of drugs to effectively treat posttraumatic stress disorder (PTSD) has become a "crisis" and has led to a significant shift in the US Department of Veterans ...

The FDA has accepted an investigational new drug application from a global biotechnology company for its investigational, ...

No new PTSD drug approvals in the U.S. in nearly 25 years; large potential addressable market for SPC-15 worldwide SARASOTA, FL, July 07, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (SILO) (“Silo” or ...

The company is also advancing commercial preparations for COMP360 in treatment-resistant depression (TRD), aiming to be ...

Compass Pathways (CMPS), on Wednesday, said the U.S. Food and Drug Administration (FDA) has accepted its Investigational New ...

(RTTNews) - Silo Pharma, Inc. (SILO) has announced a partnership with medical device company Resyca BV to conduct a drug-device study supporting the FDA IND submission for its lead asset SPC-15, an ...

An experimental drug reverses PTSD-like symptoms in mice. The corresponding study was published in Signal Transduction and Targeted Therapy and may pave the way for a new treatment for PTSD. “This ...

SARASOTA, FL, May 14, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery ...

Tonix Pharmaceuticals’ experimental drug failed to treat fibromyalgia in a recent clinical study, causing the New York–based company to focus on developing the drug as a treatment for post-traumatic ...

Silo Pharma, Inc. announced plans to submit an investigational new drug (IND) application for SPC-15, a novel intranasal treatment for Post-Traumatic Stress Disorder (PTSD), by the end of 2025, ...

Researchers are discovering that post-traumatic stress disorder (PTSD) is a significant risk factor in developing dementia. Dementia is a memory problem that affects a person's ability to carry out ...

Only two drugs are currently approved by the FDA for treating PTSD, both of which primarily target the depressive effects of the condition. In contrast, SPC-15’s differentiated method of action is ...